Newsroom | 59469 results

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics to Present on RNA-guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)...

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) announced today the commencement of tender offers to purchase for cash certain of its outstanding series of notes listed in the tables below (collectively, the “Notes”) for an aggregate purchase price, excluding accrued and unpaid interest, of up to $1.8 billion. Pool 1 Tender Offers Pool 1 Maximum Amount: $1.0 billion(1(a)) Title of Security CUSIP/ISIN Principal Amount Outstanding(in millions) Acceptance Priority Level(2) Series Tender Cap(3) U.S. Tre...

LOS ANGELES--(BUSINESS WIRE)--Turn Therapeutics, a clinical-stage pharmaceutical and medical device company, announced today that it has achieved a critical milestone in its effort to reduce dependency on cold-storage for vaccines. In partnership with the nonprofit International AIDS Vaccine Initiative, Turn Therapeutics has validated a standardized assay and demonstrated 100% recovery of vesicular stomatitis virus (VSV) -- a widely used viral backbone in vaccine development -- after both 24 an...

RALEIGH, N.C.--(BUSINESS WIRE)--Gemelli Biotech's Trio-Smart® 3-Gas Breath Test Featured at DDW 2025....

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-year to $73.5 million GAAP loss of $11.5 million, or ($0.37) per share Non-GAAP income of $1.2 million, o...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on...

MT. LAUREL, N.J.--(BUSINESS WIRE)--INTT Q1 2025 results webcast & call at 8:30am ET....

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.co...

NEWARK, Delaware--(BUSINESS WIRE)--QPS India, filial de QPS Holdings, LLC (QPS), una organización mundial de investigación por contrato de servicio completo que cumple con las BPL/BPC, ha alcanzado otro logro significativo al pasar una inspección no programada de la Administración de Alimentos y Medicamentos de EE.UU. (FDA), que se realizó del 21 al 25 de abril de 2025. La inspección consistió en una auditoría de los sistemas y procesos que concluyó con la aprobación del centro para todos los e...

米デラウェア州ニューアーク--(BUSINESS WIRE)--（ビジネスワイヤ） -- GLP/GCPに準拠し、グローバルに展開するフルサービス開発業務受託機関であるQPSホールディングス（QPS）の子会社であるQPSインドは、2025年4月21日から25日にかけて実施された米国食品医薬品局（FDA）による臨時査察を無事完了し、同社にとって重要なマイルストーンを達成しました。この査察はシステムおよびプロセスに関するもので、QPSインドがサービスを提供し、スポンサーが米国規制当局に承認申請したすべての試験について、施設が承認されたことを意味します。今回の承認は、QPSインドにとって過去20年間で46回目の規制査察合格となり、米FDA、EMA、英MHRA、WHO、ANVISA、NPRA、NABL、GCC、CDSCOによる監査とともに、QPSインドの最高水準の品質、コンプライアンス、そして科学的厳格性への揺るぎないコミットメントを裏付けるものです。 QPSインドのシニアバイスプレジデント兼マネージングディレクターであるクマール・ラムは、 「この成果は、QPSインドが品質、コンプライアンス...